Montréal, June 7, 2021 - medcomXchange and the McPeak-Sirois Group for Clinical Research in Breast Cancer are proud to announce that they are joining forces to accelerate digital health research for the benefit of the medical community and breast cancer patients. This strategic partnership between medcomXchange, a Québec-based company specializing in the development of innovative digital solutions for precision medicine, and the McPeak-Sirois Group, a charitable organization whose mission is to better fight breast cancer through clinical research, will accelerate the development of digital platforms dedicated to breast cancer.
"Over the next three years, our two organizations will jointly deploy platforms and applications powered by artificial intelligence to support breast cancer patients and ultimately provide them with access to digital therapies validated by clinical trials. A scientific committee of world leaders including the McPeak-Sirois Group is involved in the development of these treatments. It's a giant step forward that we will take in collaboration." Guy-Charles Pelletier, CEO of medcomXchange.
medcomXchange and the McPeak-Sirois Group will collaborate on three strategic areas specific to breast cancer, namely improving advanced training for physicians and researchers, supporting patients in their care and facilitating access to clinical trials. Both partners will use their expertise, resources and local and international networks.
As a first step in this partnership, the oncoXchange platform aims to foster training, networking and collaboration between physicians and researchers to accelerate the exchange of scientific data and the sharing of knowledge in precision medicine with the global scientific community.
"As our Group has done, it is essential that complementary and innovative strengths come together to provide the best technological tools and approaches for patients and the medical community. Our commitment to those affected by breast cancer will benefit from artificial intelligence through technology initiatives developed with medcomXchange," comments Dominique Johnson, general manager of the McPeak-Sirois Group. "I am very happy with this partnership which will undoubtedly promote better sharing of scientific and medical knowledge in relation to clinical research."
medcomXchange is a global digital health company dedicated to precision medicine in the field of oncology, providing cutting edge, AI-powered platforms to support physicians and their patients. Lead by a world-renowned scientific board, oncoxchange.org Breast Cancer Edition is medcomXchange's first peer-to-peer, secure digital-health platform. oncoXchange.org is the first precision-medicine platform dedicated to transforming medical education and accelerating knowledge translation into clinical practice to improve patient outcomes. Through our patient-centric application, our goal will be to empower connected patients using the latest digital education practices and providing integration with wearable devices.
About the McPeak-Sirois Group
The McPeak-Sirois Group is a charitable organization whose mission is to fight breast cancer more effectively by increasing patients' access and participation to clinical trials. The Group's scientific committee is made up of internationally renowned scientists who oversee the selection of clinical studies offered to the consortium's member hospitals. Co-founded in 2015 by Susan McPeak, a breast cancer survivor, and Charles Sirois, a wellknown entrepreneur, the McPeak-Sirois Group is committed to promoting research that cares by bringing it closer to breast cancer patients throughout Québec.
To obtain additional information or request an interview:
Flanagan Relations publiques